Metropolitan Life Insurance CO Tyme Technologies, Inc. Transaction History

Metropolitan Life Insurance CO

$253 Million
Q2 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Jul 12, 2023	BUY	$0.96 - $1.89 $36,590 - $72,037	38,115 New	38,115 $46.5 Million
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $36,590 - $72,037	-38,115 Closed	0 $0
Q1 2019 Jul 13, 2023	BUY	$1.76 - $3.73 $67,082 - $142,168	38,115 New	38,115 $67,000
Q1 2019 Mar 30, 2023	BUY	$1.76 - $3.73 $67,082 - $142,168	38,115 New	38,115 $67,000
Q1 2019 May 16, 2019	BUY	$1.76 - $3.73 $41,970 - $88,949	23,847 Added 167.14%	38,115 $67,000
Q1 2019 May 15, 2019	SELL	$1.76 - $3.73 $41,337 - $87,606	-23,487 Reduced 62.21%	14,268 $434,000
Q4 2018 Jul 13, 2023	BUY	$2.01 - $4.21 $75,887 - $158,948	37,755 New	37,755 $139,000
Q4 2018 Feb 14, 2019	BUY	$2.01 - $4.21 $75,887 - $158,948	37,755 New	37,755 $139,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.